Summary & Overview
HCPCS G9018: Zanamivir Inhalation Powder, Administered via Inhaler
HCPCS Level II code G9018 represents zanamivir inhalation powder, supplied and administered via inhaler in 10 mg units, used specifically within Medicare-approved demonstration projects. The code is important nationally because it captures billing for an antiviral inhalation therapy tied to demonstration studies, enabling tracking of utilization, reimbursement, and program participation across outpatient settings.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for inhaled zanamivir, the expected sites of service (outpatient clinics, physician offices, ambulatory centers), and what to expect from billing workflows when this demonstration-project-specific product is provided.
This publication provides benchmarks and interpretive context relevant to payers and providers, highlights policy considerations for Medicare demonstration project billing, and outlines clinical and administrative factors that affect coding and service capture for inhaled antiviral therapies. Data not available in the input where specific payer policies, common modifiers, taxonomies, ICD-10 pairings, and related codes are normally summarized.
Billing Code Overview
HCPCS Level II code G9018 describes Zanamivir, inhalation powder, administered through inhaler, per 10 mg, designated for use in a Medicare-approved demonstration project. The service is the administration of an inhaled antiviral medication formulation delivered via inhaler.
-
Service type: Drug administration (inhalation therapy)
-
Typical site of service: Outpatient clinic, physician office, ambulatory care center, or other outpatient settings where inhaled medication treatments and demonstration project services are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presenting with acute influenza symptoms (fever, myalgias, cough, nasal congestion) who is a candidate for inhaled neuraminidase inhibitor therapy in a Medicare-approved demonstration project receives zanamivir inhalation powder via a dry powder inhaler. Typical patient is an adult or adolescent with confirmed or strongly suspected influenza infection within 48 hours of symptom onset or as directed by study protocol. The clinical workflow: the patient is assessed by a clinician (primary care physician, urgent care clinician, or infectious disease consultant), influenza testing may be performed (rapid antigen or PCR), informed consent for the demonstration project is obtained when required, medication order is entered and verified by pharmacy, inhaler demonstration and counseling on inhalation technique and potential bronchospasm risk are provided, and the G9018 drug supply is dispensed and administered via the inhaler device. Observation for immediate adverse reaction may occur in the clinic for patients with reactive airway disease, and documentation includes indication, dose administered (per 10 mg unit), inhalation device used, and informed consent or demonstration project enrollment details.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit is performed and documented separately from administration of the inhaled medication |